AU2022238570A1 - Improved methods of treating diseases resulting from a maladapted stress response - Google Patents

Improved methods of treating diseases resulting from a maladapted stress response Download PDF

Info

Publication number
AU2022238570A1
AU2022238570A1 AU2022238570A AU2022238570A AU2022238570A1 AU 2022238570 A1 AU2022238570 A1 AU 2022238570A1 AU 2022238570 A AU2022238570 A AU 2022238570A AU 2022238570 A AU2022238570 A AU 2022238570A AU 2022238570 A1 AU2022238570 A1 AU 2022238570A1
Authority
AU
Australia
Prior art keywords
crfr2
agonist
maladaptation
ct38s
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022238570A
Other languages
English (en)
Inventor
Gerard PEREIRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortene Inc
Original Assignee
Cortene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortene Inc filed Critical Cortene Inc
Publication of AU2022238570A1 publication Critical patent/AU2022238570A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2022238570A 2021-03-17 2022-03-17 Improved methods of treating diseases resulting from a maladapted stress response Pending AU2022238570A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163200609P 2021-03-17 2021-03-17
US63/200,609 2021-03-17
PCT/US2022/071209 WO2022198230A1 (en) 2021-03-17 2022-03-17 Improved methods of treating diseases resulting from a maladapted stress response

Publications (1)

Publication Number Publication Date
AU2022238570A1 true AU2022238570A1 (en) 2023-09-28

Family

ID=83320930

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022238570A Pending AU2022238570A1 (en) 2021-03-17 2022-03-17 Improved methods of treating diseases resulting from a maladapted stress response

Country Status (6)

Country Link
US (1) US20250319161A1 (https=)
EP (1) EP4308150A4 (https=)
JP (1) JP2024511066A (https=)
AU (1) AU2022238570A1 (https=)
CA (1) CA3212248A1 (https=)
WO (1) WO2022198230A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025222010A1 (en) * 2024-04-19 2025-10-23 Neurocrine Biosciences, Inc. Corticotropin releasing factor receptor 2 (crfr2) agonists

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117618528B (zh) * 2023-12-01 2024-10-01 广东医科大学 一种方格星虫多肽srp及其在制备治疗急性肾损伤药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105397A1 (en) * 2009-11-04 2011-05-05 Gengo Peter J Method for treating heart failure with stresscopin-like peptides
KR20190084055A (ko) * 2016-10-20 2019-07-15 코르텐 인코포레이티드 부적응 스트레스 반응에서 기인한 질환의 치료 방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025222010A1 (en) * 2024-04-19 2025-10-23 Neurocrine Biosciences, Inc. Corticotropin releasing factor receptor 2 (crfr2) agonists

Also Published As

Publication number Publication date
CA3212248A1 (en) 2022-09-22
EP4308150A4 (en) 2025-02-19
US20250319161A1 (en) 2025-10-16
JP2024511066A (ja) 2024-03-12
WO2022198230A1 (en) 2022-09-22
EP4308150A1 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
ES2330671T3 (es) Amilina y agonistas de amilina para el tratamiento de enfermedades y trastornos psiquiatricos.
Lee et al. Comparison of dexmedetomidine and remifentanil for attenuation of hemodynamic responses to laryngoscopy and tracheal intubation
US11648295B2 (en) Methods of treating diseases resulting from a maladapted stress response
US20250319161A1 (en) Improved methods of treating diseases resulting from a maladapted stress response
EP4547218A1 (en) Tirzepatide compositions and use
Gregoretti et al. Clonidine in perioperative medicine and intensive care unit: more than an anti-hypertensive drug
Abboud et al. Essential tremor: choosing the right management plan for your patient
AU2006341375B2 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
Agarwal et al. Multimodal analgesia for perioperative management of patients presenting for spinal surgery
US20160256417A1 (en) Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder
Ekbom et al. Effects of midazolam and nitrous oxide on endocrine and metabolic measurements in children
JP6567971B2 (ja) 女性性機能障害の治療におけるブレメラノチドの使用
US20090181890A1 (en) Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
Yadav A Comparative Study of Efficacy of Lignocaine (1.5 mg/Kg) Versus Dexmedetomidine (1 µg/Kg) in Attenuating Haemodynamic Response to Laryngoscopy and Endotracheal Intubation–A Clinical Study
Raffaeli et al. Intrathecal drug administration for the treatment of cancer and non-cancer chronic pain